Sign Up
OverviewAPI
Xaira Therapeutics, a new AI drug discovery startup, secures a substantial $1 billion in funding to pioneer drug development through cutting-edge AI models. Led by seasoned CEO Marc Tessier-Lavigne, the company embarks on creating innovative drugs with the promise of overcoming prior limitations, despite investor hesitations regarding his Stanford history.

Ask a question